Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2018-12-07T16:30:35Z | - |
dc.date.available | 2018-12-07T16:30:35Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1949-2553 | * |
dc.identifier.other | OAK-20863 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247363 | - |
dc.description.abstract | Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM. Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS). Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. = 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. = 35.1 mg/ m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP. In conclusion, VMP is a feasible and effective front-line treatment for transplantineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients. © Kim et al. | * |
dc.language | English | * |
dc.publisher | Impact Journals LLC | * |
dc.subject | Aged | * |
dc.subject | Bortezomib | * |
dc.subject | Combination | * |
dc.subject | Drug therapy | * |
dc.subject | Multiple myeloma | * |
dc.title | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | * |
dc.type | Article | * |
dc.relation.issue | 23 | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 37605 | * |
dc.relation.lastpage | 37618 | * |
dc.relation.journaltitle | Oncotarget | * |
dc.identifier.doi | 10.18632/oncotarget.16790 | * |
dc.identifier.wosid | WOS:000403236400058 | * |
dc.identifier.scopusid | 2-s2.0-85020194784 | * |
dc.author.google | Kim M.K. | * |
dc.author.google | Kim K. | * |
dc.author.google | Min C.-K. | * |
dc.author.google | Kwak J.-Y. | * |
dc.author.google | Bae S.-B. | * |
dc.author.google | Yoon S.-S. | * |
dc.author.google | Lee J.-J. | * |
dc.author.google | Kim K.H. | * |
dc.author.google | Nam S.-H. | * |
dc.author.google | Mun Y.C. | * |
dc.author.google | Kim H.J. | * |
dc.author.google | Bae S.H. | * |
dc.author.google | Shin H.-J. | * |
dc.author.google | Lee J.-H. | * |
dc.author.google | Park J.S. | * |
dc.author.google | Jeong S.H. | * |
dc.author.google | Lee M.H. | * |
dc.author.google | Kim Y.-S. | * |
dc.author.google | Lee H.S. | * |
dc.author.google | Park K.W. | * |
dc.author.google | Lee W.-S. | * |
dc.author.google | Lee S.M. | * |
dc.author.google | Lee J.-O. | * |
dc.author.google | Hyun M.S. | * |
dc.author.google | Jo D.Y. | * |
dc.author.google | Lim S.-N. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Cho D.-Y. | * |
dc.author.google | Do Y.R. | * |
dc.author.google | Kim J.-A. | * |
dc.author.google | Park S.K. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Kim S.-J. | * |
dc.author.google | Kim H. | * |
dc.author.google | Yi H.G. | * |
dc.author.google | Moon J.H. | * |
dc.author.google | Choi C.W. | * |
dc.author.google | Kim S.-H. | * |
dc.author.google | Joo Y.D. | * |
dc.author.google | Kim H.-G. | * |
dc.author.google | Kim B.S. | * |
dc.author.google | Park M.-R. | * |
dc.author.google | Song M.-K. | * |
dc.author.google | Kim S.-Y. | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |